Nexus Awards go to Cleveland Clinic's Dennehy, Quadrant's Boorjian

Share this article:
The Association of Medical Media (AMM) named Joe Dennehy of the Cleveland Clinic and Megan Boorjian of Quadrant as its 18th annual Nexus Representatives of the Year, an accolade given to outstanding sales professionals in the field of medical publishing.

Dennehy took the award for multi-specialty publication home to the Cleveland Clinic Journal of Medicine, and Boorjian claimed the specialty publication award for Quadrant's Pulmonary Reviews. Nexus award recipients were selected based on their performance in both print and online this year, according to an AMM statement.

The event, held March 18 at Inside Park at St. Bart's in New York City, was presided over by keynote speaker Ron Pantello, former CEO of Euro RSCG Life Worldwide and founder of the Medical Advertising Hall of Fame. This year's event was presented in a new cocktail reception format.

Pantello told the assembled group of around 160 that success moving forward would require medical publishers to "create channels, leveraging interactive, social and digital technology that better connects readers with content, authors, colleagues and medical societies for enhanced engagement," according to the statement.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...